Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Deferred Revenue (2023 - 2025)

Immunome (IMNM) has disclosed Current Deferred Revenue for 3 consecutive years, with $4.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Deferred Revenue fell 68.5% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Mar 2025, down 68.5%, and an annual FY2024 reading of $6.9 million, down 56.57% over the prior year.
  • Current Deferred Revenue was $4.0 million for Q1 2025 at Immunome, down from $6.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $27.6 million in Q1 2023 and bottomed at $4.0 million in Q1 2025.
  • Average Current Deferred Revenue over 3 years is $14.4 million, with a median of $12.7 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue tumbled 42.92% in 2024, then tumbled 68.5% in 2025.
  • Year by year, Current Deferred Revenue stood at $16.0 million in 2023, then tumbled by 56.57% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IMNM at $4.0 million in Q1 2025, $6.9 million in Q4 2024, and $9.7 million in Q3 2024.